Home / Transcripts / Glanbia plc (GL9) · November 4, 2026

Glanbia plc (GL9) Earnings Call Transcript

November 4, 2026

ISE IE Consumer Staples Food Products interim_update 39 min

Earnings Call Speaker Segments

Operator operator
#1

Good day, and thank you for standing by. Welcome to Glanbia's Third Quarter 2026 Interim Management Statement Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I'd now like to hand the conference over to Mr. Liam Hennigan, Group Secretary and Head of Investor Relations. Please go ahead, sir.

Liam Hennigan executive
#2

Thank you. Good morning, and welcome to the Glanbia Q3 2026 Interim Management Statement Call. During today's call, the directors may make forward-looking statements. These statements have been made by the directors in good faith based on the information available to them up to the time of their approval of the interim management statement. Due to the inherent uncertainties, including both economic and business risk factors underlying such forward-looking information, actual results may differ materially from those expressed or implied by these forward-looking statements. The directors undertake no obligation to update any forward-looking statements made on today's call, whether as a result of new information, future events or otherwise. I'm now handing the call over to Hugh McGuire, CEO of Glanbia plc.

Hugh McGuire executive
#3

Thank you, Liam. Good morning, everyone, and welcome to the Glanbia Quarter 3 2026 Interim Management Statement Call and Presentation. On today's call, I will provide an overview of our performance for the first 9 months of the year. I'm joined by my colleague, Mark Garvey, who will cover the outlook. At the end of the presentation, we will be happy to take your questions. Overall, the group had a strong performance as we continue to execute on our strategy, supported by structural trends across our markets with growing protein consumption and increasing focus on health and wellness. Year-to-date, our like-for-like revenue increased by 9.9% to $3.2 billion with volume growth across all 3 segments. In Performance Nutrition, like-for-like revenue increased by 18% year-to-date as we continue to see strong consumer demand in the protein and energy categories. with Optimum Nutrition continuing to outperform the protein powder category and gain market share with like-for-like revenue growth of 25.8%. In Health & Nutrition, we saw continued momentum in priority end-use markets with like-for-like revenue growth of 9.8% year-to-date. And in Dairy Nutrition, we saw volume and pricing growth across protein Solutions, somewhat offset by market pricing in cheese. I'm delighted to have Wendy Chang Smith appointed as CFO Designate, ahead of succeeding Mark next year, and I look forward to a smooth transition. As a result of the strong performance across all 3 segments, we are today pleased to upgrade our full year adjusted earnings per share guidance to 22% to 24% constant currency growth. This will be driven by strong top line performance in Performance Nutrition and Health & Nutrition and continued earnings momentum in dairy nutrition, supported by our group-wide transformation program. Mark will provide a detailed update on changes to segmental guidance. Performance Nutrition performed ahead of expectations during the third quarter, with year-to-date like-for-like revenue increasing by 18%, driven by a 4.3% increase in volume and a 13.7% increase in pricing. The volume growth was driven by strong category and velocity growth, coupled with increased distribution, market share gains, innovation, some shipment timing in quarter 2 and a weaker comparative in the first half of the year. Volumes declined by 4.7% in quarter 3, primarily as a result of tougher comparable in the U.S. region due to new distribution gains in the prior year and margin dilution promotional activity not repeated this year. Optimum Nutrition performed ahead of expectations with 0.8% volume growth in quarter 3 despite pricing greater than 20%. Pricing growth was driven by pricing actions taken over the last 12 months, with the most recent price increases implemented in quarter 3 in response to weight cost inflation. We have seen an initial softening in some high-end whey prices in the last couple of months but remain at elevated levels in line with earlier this year. We continue to monitor the situation closely with our estimated we need substantially procured for half 1 2027. The visibility and insights that we build through our integrated model and procurement program is an important input into our pricing, revenue growth management model and margin planning. Following our recent price increases, we've seen some elasticity concentrated in specific channels and pack side, but underlying consumer demand remains resilient, supported by the higher income skew of our shopper base and [ ON and ISR ] brand stream. We continue to monitor elasticity and remain disciplined in our approach, balancing the need to manage the cost environment with protecting consumer value and the long-term health of our brands. From a regional perspective, PN Americas, which represents 60% of revenue, increased year-to-date like-for-like revenue by 11.9% versus the prior year, with strong growth in Optimum Nutrition somewhat offset by declines in other portfolio of brands. PN International, which represents 40% of revenue, delivered like-for-like revenue growth of 28.3% in the year-to-date, with strong growth in measured consumption across priority markets and continued momentum in both protein powders and creatine. Optimal Nutrition, which represents 79% of Performance Nutrition revenue, delivered like-for-like revenue growth of 25.8%, growing ahead of the category and gaining market share. We continue to focus on driving recruitment and conversion of new consumers, supported by innovation as we expand usage occasions. We also continue to invest across our brands to drive market share growth. including a double-digit increase in marketing spend on Optimum Nutrition this year, and we are planning for a similar increase in investment next year. U.S. consumption increased by 22.9% in the 13 weeks, third October, with strong double-digit growth across core channels, growing ahead of the category. We saw continued growth in our household penetration and distribution. We're also seeing resilient consumption across measured international markets with strong double-digit growth. Isopure saw strong growth in online and food drug mass channels, offset by declines in the club channel, primarily reflecting reduced distribution in the club channel. We will fully lap that impact by end of year. Isopure also saw good double-digit growth in household penetration and total distribution points. As a result of the continued strong momentum in the third quarter, which we see continuing into the fourth quarter, we are pleased to upgrade our full year like-for-like revenue guidance to 16% to 17% constant currency growth. Health & Nutrition delivered a strong performance year-to-date, delivering like-for-like revenue growth of 9.8%. This was driven by 11.5% increase in volume and a 1.7% decrease in price. Total revenue increased by 12.8% as a result of the 3% increase from the acquisitions of Sweetmix and Scicore. We're pleased with the continued momentum across our end-use markets of active nutrition, functional beverages and vitamin & mineral supplements, supported by strong underlying category momentum in protein and broader health and wellness trend. As we noted previously, growth in the first half benefited from some incremental customer-led innovation activity. In quarter 3, growth returned to a more normalized level. Given the nature and timing of customer innovation programs, we can see some variability in growth from quarter-to-quarter, but the underlying momentum in the business remains strong. Regionally, we saw strong growth, particularly in EMEA and Asia Pacific, Pricing was slightly negative as a result of certain volume rebates for customers throughout the year and due to tariff refunds to customers in the second quarter. The integration of our recent acquisitions of Sweetmix in Brazil and Scicore in India are on track, and our capacity expansions in the U.S., Europe and China are progressing well, with new capacity expected by early 2027. We remain ambitious to scale this business further through acquisition. We continue to see strong demand for our high-quality protein solutions and bioactives driven by global trends in active nutrition and everyday wellness, supported by our expertise in protein innovation, position us as a partner of choice for customers seeking premium science-led protein solutions. Year-to-date, like-for-like revenue in dairy nutrition increased by 2.1%, driven by a 1.4% increase in volume and a 0.7% increase in price. The volume increase year-to-date was driven by Protein Solutions, with strong whey protein demand, particularly targeting the high-protein healthy snacking category. We continue to see good demand for colostrum, targeting go health and immunity as we evolve our innovation and fractionation to deliver peptides that deliver immunity and other bioactive benefits to consumers. The volume decline in quarter 3 was primarily driven by customer-related timing effects for some commodity-linked products. Pricing is driven by double-digit pricing in whey protein solutions, somewhat offset by declines from market pricing in these markets. And with that, I will hand over to Mark.

Mark Garvey executive
#4

Thanks, Hugh, and good morning to everyone on the call. The group has a strong balance sheet at the end of the third quarter, net debt was $704 million. Capital expenditures, both strategic and business sustaining initiatives for the year are expected to be between $100 million and $110 million, with investments primarily related to capacity expansions within our Health & Nutrition segment, as well as group-wide business integrations and digital investments to drive further efficiencies in operations. In February, we announced authorization for a EUR 100 million share buyback program. This program was completed in 2 tranches; EUR 50 million and by way of our regular share buyback program, which was executed from March through July and EUR 50 million in June through a directed share buyback with Tirlan, our large shareholder. In total, in 2026, the group repurchased and canceled approximately 4.9 million shares at an average price of EUR 20.49. Approximately EUR 102 million in dividends were also returned to shareholders this year, in line with our progressive dividend payout ratio of 30% to 40% of adjusted earnings per share. Now let me turn to our fiscal '26 outlook. We are ambitious for growth that we outlined our medium-term growth algorithm at our Capital Markets Day in November 2025. given our position at the heart of better nutrition and the strong momentum we are seeing this year in the categories in which we operate, our expectations for 2026 are above our medium-term growth algorithm. Following the strong performance year-to-date, performance nutrition like-for-like revenue growth is now expected to be in the range of 16% to 17% for the year, which assumes some volume elasticity in Q4 following cumulative pricing actions. We expect Q4 volumes for Performance Nutrition and Optimum Nutrition to be broadly in line with Q3 volume rates with a tougher comparable in PN international in Q4. The Q4 year-on-year pricing contribution will moderate some back from Q3 as we lapped Q4 pricing from last year. We continue to manage our way needs through layered forward procurement. And at this point, we have substantially procured our estimated rands for the first half 2027. Based on procurement to date, we are seeing higher costs in the first half of '27 over 2026, and reflecting continued strong demand. And consequently, we will consider the need for additional price increases as appropriate in early 2027, following further visibility and full year '27 whey costs. Performance Nutrition EBITDA margins are expected to be higher in the second half of this year compared to the first half as a result of executed pricing actions. On the full year, we continue to expect some margin progression over the 13% EBITDA margin in 2025. We are continuing to offset higher whey costs with pricing, revenue growth management initiatives and our group-wide transformation program while also ensuring continued investment behind our brands. Health & Nutrition delivered a strong performance in the first 9 months of the year with some benefit from timing of orders from certain customers in the first half of the year. Growth in Q3 was within our medium-term guidance range of 4% to 6% and and we continue to expect fiscal '26 like-for-like revenue growth in the range of 8% to 10%, with Q4 volume growth expected to be lower than Q3 growth as a result of the phasing of some orders from customers. Underlying end market growth remains in line with our medium-term growth algorithm. We continue to expect Health & Nutrition EBITDA margins to be in the range of 17% to 19% and with increased costs in the second half resulting from supply chain disruption resulting from the conflict in the Middle East. The strong performance in dairy nutrition in the first 9 months of the year was driven by pricing and volume growth in protein solutions, serving the high protein ready-to-agent healthy snacking categories. Following the strong performance year-to-date, we now expect Dairy Nutrition EBITDA will be in the range of $175 million to $180 million for the full year. We expect the group's share of profit after tax of the joint venture to marginally exceed $20 million for the full year. Operating cash flow conversion is expected to be at least 85% for the year, in line with our medium-term target, and net debt to EBITDA is expected to be approximately 1x at year-end. Therefore, as a result of the expected improved revenue performance in Performance Nutrition and continued strength in dairy nutrition and our joint venture we are pleased to upgrade our expectations for 2026 adjusted earnings per share growth to a range of 22% to 24% constant currency. And with that, I will hand it back to the operator, and we will be happy to take your questions.

Operator operator
#5

[Operator Instructions] And our first question comes from the line of Patrick Higgins from Goodbody.

Patrick Higgins analyst
#6

Three questions, if that's okay. Firstly, just for Mark. First, just said, congrats on the retirement announcement and all the best with the next chapter, but maybe just going to the end pricing. A big step-up there, 25% growth in Q3, materially ahead of the mid-teens we had expected a big step up for the 12% in Q2. Maybe you could just bridge the step-up in terms of the annualization and the phasing of price increases versus maybe lower promotional intensity and better mix? Second question then maybe on [ The ON ] volume resilience. Obviously still positive despite the scale of the pricing taken and the really strong prior comp. Maybe you could just impact what's driving that resilience between underlying category growth, share and distribution gains and then innovation, particularly around creating, I guess? And then my final question is just -- just around the competitive environment into Q4 and 2027 as whey costs ease. Do you expect an increase in promotional activity as as whey costs given the pullback in whey cost? Or how do you think the industry will prioritize, I guess, rebuilding margins versus driving volumes?

Hugh McGuire executive
#7

Thank you very much for that. I suppose the first question on Optimum Nutrition pricing. When I say look at a strategic level, it's a cumulative effect of 3 price increases over the last 12 months. So that's what drove the big pricing increase in quarter 3. We will lap that first price increase. That first price increase was put in early quarter 4 last year, so we'll lap that down for this year. I think pleasing as we've seen the business demonstrates very disciplined pricing execution. I've spoken about it before, how we consider to deliver us around how we've approached pricing actions across the last 12 months as we make sure we continue to capture share and consumer demand. And I think as well, you said it yourself, good price realization in the quarter across our portfolio. And from my perspective, I suppose we are positive is to see such strong price realization complemented by that healthy consumption growth, which you've seen in [indiscernible]. Optimum Nutrition, yes, look, I think we said it on our calls, we'll always be prudent as we look ahead, as we look -- as we price increase as well and just carefully monitor consumer reaction. I think what we're continuing to see, though, is continued strong category demand globally driven by the health and wellness and protein trends that we've spoken about before. We continue to capture share. I think that's driven by our marketing investments. And bottle drive most of it really it is category growth and velocity as we take share rather than innovation. They are the 2 big drivers of consumption. Creating, yes, we called it out, continues to perform strongly, so pleased to see the performance across both our protein and creating categories. And lastly, the competitive environment whey. Look, I suppose what I'd say on whey fundamentally the whey price drop is good for the group. We're a far bigger buyer of high-end whey proteins than we are a manufacturer. So a reduction in whey prices overall is good. It clearly benefits our PN margin business, it might impact DN a little negatively, but majority of our protein business in DN now is in solutions, so it means it's more insulated. What we see is certainly, from our perspective, while we've seen some pullback in pricing. On 1 particular variant only, this is after a record spike in price in quarter 2, quarter 3 in October. 80% of a price increase in those couple of quarters. So while it's now office record highs, it's now only back to where it was earlier this year. and still substantially ahead of last year and long-term averages. So from our perspective, we'll continue to watch carefully. Whey demand remains robust. We can see that across our integrated model. So in terms of price increasing for next year, we'll keep it under review. We'll watch carefully as we go to early next year, but we will likely be pricing in half or next year on our protein runs. .

Mark Garvey executive
#8

And I would just add, thank you for your kind words, appreciate this. And as Hugh says, I mean, if you think about the upgrade we just have here for Performance Nutrition, it's the ON resilience, as you said yourself, elasticity coming in a bit better. We anticipate that the execution of the pricing realization has come in a bit better than we expected as well. So all of that, of course, has led us to be comfortable upgrading the top line for PN.

Operator operator
#9

Thank you. We will now move to our next question from the line of Cathal Kenny from Davy. .

Cathal Kenny analyst
#10

My first question, Mark, is just can you reconfirm your comments on volumes for ON for Q4, please? That's my first question. Second question, looks like the Performance International was very strong. Perhaps you could isolate the performance of Opto Nutrition International in Q3 and what were the drivers of that? I know in the prepared remarks, you mentioned innovation and distribution gains, but if you could elaborate further on that, we welcome final question then is on margin and just looking at the context of a much stronger revenue performance, Performance Nutrition, but you've held your margin commentary for the full year in terms of preparation that infers some reinvestment in marketing spend in the back half of '26. They are my 3 questions. .

Mark Garvey executive
#11

Cathal, I'll take the first and third and then pass to Hugh for the second. So in terms of Optimum Nutrition, yes, just reconfirming my comments, I just wanted to will give some view as to probably expect volumes to be in the fourth quarter for PN and for ON. So yes, we expect Optimum Nutrition volume profile to be similar in the fourth quarter what we saw in the third quarter, which, again, we're pleased to see. It will be more Americas and International. We are lapping some distribution gains in international in the fourth quarter last year, so it will be more of an Americas, I suppose, volume profile for ON in the fourth quarter. In terms of margins, yes, clearly, pricing does help. But I think you might recall at the second -- at the half year, I did say that to the extent that elasticity can know a little bit better than we expected, we would be using some higher cost wages. That does feed in the formula as well. We continued our marketing investment, our marketing investment this year actually be around 6%, similar to our road last year. where the cost, the top line has done, that means there's a significant volume, a nominal increase rather in the dollar spend there in marketing, which we're happy with as well. . With that, open over to you. .

Hugh McGuire executive
#12

Just to speak to performance international yes, continued trends that we would highlight at the half year of good performance across all of our kind of Tier 1 marketplaces. So that be China in New Europe U.K. So it's a good strong performance. Remember, international is primarily up to efficient, although we have seen very strong performance right of Europe in India also. So your continued strong consumption and double-digit consumption on both key markets, again driven by the health and wellness trends that we've spoken in the past. We'll see that come back a little bit in quarter 4, also against tougher comps in our international business. but overall trends remain very strong.

Operator operator
#13

And our next question comes from the line of Ana Nogueira from Berenberg.

Ana Nogueira analyst
#14

Congratulations on the Q3 results, I have 1 question on Performance Nutrition volumes in Q3. Given that Optimum Nutrition volumes were positive, while the division overall declined. Could you give some color on what drove the volume declines of other brands and how price elasticity and competitive intensity has evolved during the quarter .

Hugh McGuire executive
#15

Ana, yes, no real change to competitive intensity. I think consumption remains very strong, driven primarily Optimum Nutrition. The decline in other portfolio of brands is, as we spoke about half year results. And I highlighted in the call earlier, Isopure is a big driver of it, which is -- we're very happy with Isopure growth in food drug mass channels, double-digit consumption growth, but we had a club channel business last year that we no longer have. And we will comp that at the end of this year. we would see Isopure back in growth in the U.S. in North America market from the start to 2027. And then think our ready-to-eat high protein bar, we're relaunching that. We've lost some distribution, but we have a major relaunch coming in quarter 2 this year. So again, that's the driver of the decline in the overall number is driven primarily by Isopure but will be -- that should turn in 2027.

Operator operator
#16

We will now move to our next question from the line of David Roux from Morgan Stanley. .

David Roux analyst
#17

Mark, and well done on the results. I've got 3 questions from my side. Firstly, on Performance Nutrition pricing. I think in the update in August, you mentioned you were looking to take an additional pricing in Q3 and then either late in '26 or early '27. Could you update us on whether these have or are playing out as you had expected? And then my last 2 questions relate to your comments around whey procurement. How much flexibility do you have in your overall whey procurement from your suppliers given the spot market is rolling over or should we consider your cost base through the first half of next year largely fixed? And then my last question, sort of building on from this. Can you confirm if costs in '27 are still expected to be higher than '26. I note that you mentioned you're pulling forward some of the higher cost whey given the lower elasticities at the minute? And then also, any quantification on how much higher you think cost will be next year versus the aggregate of '26.

Hugh McGuire executive
#18

David. Maybe just talk to the whey point first. If you asked a large fit, we got flexibility in a whey procurement. We have a layered approach. Obviously, our integrated model across B2B and B2C gives us great visibility. We did see significant spikes in quarter 2 and quarter 3 on a single variant of whey. We won't have bought at the high end of that market, and we're buying right now at the lower end of the market. So that will start to flow through next year. So we have phasing in how we approach our our procurement. And it wouldn't be as fixed, maybe as you suggest, we put flexibility around that as well. But we will see higher whey costs in early 2027 off the back of some of those prices we saw in quarter 2 and quarter 3. As I said, fundamentally, we continue to see those prices still remain substantially higher than they were earlier on in the year. And it's only 1 variance that we saw a drop on. We haven't seen a drop in other variance in demand as we see from our B2B dairy nutrition business is good. In terms of pricing, what we said is we -- I think in my half year results, I said we would be reviewing pricing and may have to consider a price increase at the end of '26 or early '27 What I've also said is we're -- we've been very disciplined in how we approach our pricing. So watching ahead on input cost inflation, watching ahead on consumption competitor reaction market, et cetera. So we won't be -- we do believe we still have a price increase in 2027, but it's more likely in half 1, we won't be price increases between now and the end of the year, but we'll continue to keep that under review. .

Mark Garvey executive
#19

Yes. David, just in terms of quantifying, I mean it's too early for me to quantify at this point. But as Hugh said, -- as you look at early next year, there is some higher weight that we would have for this year. But we are layering in our procurement. We've got great relationships with our suppliers. And as we look to next year, we'll update you in February in terms of how that will go.

David Roux analyst
#20

That's very helpful. Just perhaps just a follow-up question on that. So yes, it's quite clear you have a lot of flexibility on the phasing, et cetera. But when it comes to the actual contracts with your customers, if you locked into, say, a delivery in, say, April next year, do you have flexibility in renegotiating that lower just given the size of yourselves as customers? .

Hugh McGuire executive
#21

Yes. I think you mean by suppliers. Yes, what I'd say today but without getting into specifics of our callers for suppliers is we don't believe we're at any competitive disadvantage in terms of our whey procurement. And you can well imagine that the way we're buying now will benefit in quarter 2. So we moved through whey supplies very quickly. So we're not at any competitive discipline.

Operator operator
#22

And our next question comes from the line of Karel Zoete from Kepler Cheuvreux.

Karel Zoete analyst
#23

I have 2 follow-up questions. The first one, I know it's early days, but we already mentioned 2027 a few times. Given the incremental pricing in H2 this year and further increase in '27, how should we think about your 5% to 7% medium-term growth outlook for PN in '27 and related to the medium-term ambitions for PN, the margin improvement of 250 basis points I shared last year at the CMD, is that still possible to achieve given the elevated level of whey prices we've seen? And the second question is, please, if you can provide a bit more details with regards to what you're seeing in the U.S. with the design for value pack size program, et cetera. Where do you see more elasticities and were less? And any help on that there .

Hugh McGuire executive
#24

Karel, I won't give you 2027 guidance, but I presume it's clear that as you look at the lapping and price increase you're seeing this year, that's going to continue into next year. So probably not expected that we would be at least about above our 5% to 7% for next year because the pricing abalone but we'll confirm all that, obviously, in February. From a margin perspective, we are still we're still focused on getting that 250 basis point improvement through 2028. And I said on the last call that we're -- obviously, it is taking a little longer because of the fact that whey costs have increased significantly. We are seeing some stabilization now, potentially some reduction in 1 element. We'll see how that plays out. but our pricing has been executed, I think, very, very well for us to continue to catch up on that. Importantly for us, this transformation program of $70 million also kicks in fully next year. And that will obviously be a significant benefit for us in helping our margin and giving us some space also to increase even behind our brand. So I declare or the progression next year. .

Mark Garvey executive
#25

Yes, Karel, from an elasticity perspective, you specifically mentioned the U.S. I think first and foremost, I suppose we'll always look at consumption numbers. And our consumption numbers when you look at U.S. consumption, last 13 weeks at 23%, 22.9% are very strong for ON. So same international markets as well, very strong double-digit consumption in all of the markets that we measure. So very happy with continued demand. And I think that's the fundamental demand remains strong. Yes, we have seen limited elasticity. We've seen some trading down from GBP 5 to GBP 2, but we've also seen some trading up in GBP 5 to GBP 10 in protein. So I think what I'd say is it's still too early to call. Demand remains robust. Quarter 4 started well. But it's again something we keep under review.

Operator operator
#26

And our next question comes from the line of Alex Sloane from Barclays. .

Alexander Sloane analyst
#27

Best wishes for Mark and good to see working capital clearly well managed in the quarter as usual. Two questions. Really, 1 was coming back to the whey procurement now there's been a lot of questions there, but to your comment that you don't think you're any kind of fundamental disadvantage. So just to kind of maybe dig in on that a little bit. So you basically don't see a risk because that in H1 of next year, if you have to take pricing up again because whey costs are higher, the competition in aggregate has much different procured way. So at that point could be cutting prices based on the falling spot rate. Is that the right sort of understanding there? And then I guess, secondly, just on the WPC80 pull back, which I think probably is a bit more extreme than most we're expecting over the last couple of months. What's your read on kind of what's driven that? Is that reformulation for that specific grade? Or is this kind of a signal that maybe we're sort of at the top as regards to kind of demand for protein, do you think? And do you think there's any -- I mean, what was the historically, what would you expect this pullback in WPC80 to kind of feed through into WPI to the same extent over time? Or do you think this time is a bit different. .

Hugh McGuire executive
#28

Thanks, Alex. Yes. I suppose the first thing maybe just start with the overall markets and overall demand. Our integrated model across B2B and B2C gives us great early insights and read on the dairy and whey markets. And fundamentally, what we see right down to even drive way and [indiscernible] which is the raw material is a very continued very strong demand for whey protein. I will hear that from my Dairy Nutrition business. When you think about the WPCA, pulled back and like what we saw a quarter -- and it was a spike in price. We went to up 80% to 100% in the past 2 quarters. So what drove that? There's a degree of trading, there's a degree of emotion in this as well. Clearly, we had strong demand -- but it's now all its record highs. It's back to where it was in quarter 1, which is still substantially ahead of what it was in prior year. So whey pricing still is robust while certainly in 1 variant it's come back. But a comeback record spike in price. What's driven that? I think probably a couple of 3 probably things. One, I think, yes, we probably have it at that variance whey. We have seen some wind formulation and some industries using cheaper variants of different proteins, but there's only so much of that you can do. I think the second thing, remember, a lot of the dairy plants have a variability can switch manufacturing across different variants. They can switch from 80 to 90 is the right way. So what we would have seen is given the high whey price and the whey prices, particularly manufacturers switched into 80s and that switched back into 90. So given those prices pull back. So -- there's a lot of complexity and moving bits and pieces in this. I think the -- your answer to the spot market. Yes, so could somebody be could somebody discount based on the fact that they have had no inventory and bought off spot in quarter 3 and into quarter 4 for early next year potentially but most of our competitors are of scale. They have in just like we do it and take time to flow through. And what we're seeing is, in reality, this is a kind of a quarter lift -- and we'll either go back to the long-term fundamental demand on way across our entire portfolio and the long-term fund and demand for protein remains strong.

Operator operator
#29

Our next question comes from the line of Damian McNeela from Deutsche Bank. .

Damian McNeela analyst
#30

A few for me, please. Firstly, just on the strong consumption, I was wondering whether, Hugh you could provide some insight into the extent to which that's being supported by new consumers entering the category, whether you've got any data points you can share around that, please? Second 1 is just on marketing. I think you talked about strong double-digit increase in support for ON and you had a sort of 6% of revenues for the group this year. Can you sort of provide any insight into the sort of level of marketing support for the other brands within PN? And then just 1 final one. you talked about the ambition to do more M&A in H&N. Can you just sort of provide us an update on the sort of the pipeline and the potential sort of outlook for sort of doing more deals in the sort of the next 12 months or so, please?

Hugh McGuire executive
#31

Consumption, I suppose what I'd say again, just overall, I'm very pleased with consumption in the U.S. and globally continue to see new consumers coming into the market. I think the way we would offer -- we would track that is household penetration, and we see strong growth in household penetration, double-digit growth as penetration in about half, 2/3 of that would be driven by new consumers into the category. So that's the most pleasing thing. And I've called it out in terms of where we focus our brand spend as well. That's a key focus area for us is to make sure we drive awareness of our brands for those new consumers coming into the category that we recruit them into our brand. And a lot of our brand investments are quality, our heritage, first element, I've said it before, we're the most recommended most reputed brand there in Optimum Nutrition. So that's a key focus for where we invest our money. We have double-digit increase in our marketing spend in Optimum Nutrition this year in terms of dollars. We would be the same again next year. [indiscernible] brand. I think we were clear confidence that the 3 brands with our priority investment in our protein brands, of Optimum Nutrition, Isopure and ON. So they are the brand and continue to prioritize our brand spend around and we will continue that for an extra thing. Obviously, until we relaunch next year, we pulled back on some of that marketing spend but you'll see a big increase in support for the [indiscernible] brand from quarter 2 of next year. And lastly, just in terms of M&A pipeline, we are very acute. I suppose our challenges all this is with good financial discipline. So some of the valuations that are out there are a little bit frothy. So making sure that we have a very active pipeline but making sure we we acquire the right assets at the right price or the right return continues to be a key focus for us. But as we said at our capital markets, we are ambitious to scale health and nutrition more.

Operator operator
#32

Thank you. We have now reached the end of the question-and-answer session. I'd now like to turn the conference back to Mr. Hugh McGuire for his closing comments. .

Hugh McGuire executive
#33

Thank you very much, operator. Yes, just to say thank you all for your questions and look forward to meeting with you over the next couple of weeks.

Operator operator
#34

Thank you for your participation in today's conference. This does conclude the program. You may now disconnect your lines.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Glanbia plc transcript - plus 261,000+ transcripts from 13,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Glanbia plc earnings transcripts and 261,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $145 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.